Interleukin-2 receptor antibody does not reduce rejection risk in low immunological risk or tacrolimus-treated intermediate immunological risk renal transplant recipients

ANZDATA
Article
  • Posted15 Apr 2010
  • PMID20470309

Periodical/sNephrology (Carlton)